Objectives Lymphogranuloma venereum (LGV) infections caused by Chlamydia trachomatis L types have recently emerged in Europe among HIV-positive men having sex with men. Our aim was to introduce a genotyping strategy suitable for a diagnostic laboratory using nucleic acid amplification tests (NAATs) for detection of C trachomatis and to investigate the prevalence of LGV types in rectal and pharyngeal specimens in Finland.
Methods Aptima Combo 2 (Gen-Probe) was used to detect C trachomatis in swabs. Altogether 140 C trachomatis NAAT-positive rectal and pharyngeal samples were genotyped by pmpH and ompA real-time PCR.
Results Of the 140 NAAT-positive rectal and pharyngeal specimens, 114 (81%) were successfully typed by pmpH PCR. One hundred and four samples contained non-LGV, nine samples LGV and one sample both non-LGV and LGV C trachomatis types. The C trachomatis LGV types were mainly found in rectal samples. Six of the L types were confirmed to be genotype L2b and two were L2 with ompA PCR and sequencing.
Conclusions Our experience suggests that genotyping C trachomatis by pmpH PCR can be introduced as a function of a diagnostic laboratory already using NAAT for detection of C trachomatis. The data show that LGV infections occur also in Finland. LGV should be taken into account when considering treatment and management of rectal C trachomatis infections.
- Chlamydia trachomatis infections
- lymphogranuloma venereum
- chlamydia infection
- molecular epidemiology
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Presented in part: 12th International Symposium on Human Chlamydial Infections, Hof bei Salzburg, Austria, June 2010 (abstract pp. 405–408).
Funding This study was supported by an R&D grant from Helsinki University Central Hospital, Laboratory Division (HUSLAB), MLE82TK013, by The Finnish Society against Sexually Transmitted Diseases and by the Academy of Finland in the frame of the ERA-NET PathoGenoMics, #217554/ECIBUG and #130043/ChlamyTrans.
Competing interests None.
Ethics approval The Ethics Committee, Department of Medicine at Hospital District of Helsinki and Uusimaa.
Provenance and peer review Not commissioned; externally peer reviewed.